Literature DB >> 7117357

Hepatic blood flow and drug metabolism in patients on enzyme-inducing anticonvulsants.

H I Pirttiaho, E A Sotaniemi, R O Pelkonen, U Pitkänen.   

Abstract

Liver blood flow and indices of hepatic drug metabolism (antipyrine elimination rate and cytochrome P-450 concentration in liver biopsy specimens) were studied in 19 epileptics on long-term anticonvulsant treatment, and in 18 controls. The size of the liver and the total estimated liver blood flow were greater inthe epileptics than in the controls, whereas the relative liver blood flow (per unit weight of the liver) was not significantly different. The epileptics had higher cytochrome P-450 levels and they eliminated antipyrine faster than the controls. It was concluded that long-term ingestion of enzyme-inducing anticonvulsants is associated with an increase in the total hepatic blood flow in parallel with the increase in liver size, and not as an independent phenomenon. Since the relative perfusion rate of the hepatocytes was unchanged, the enhanced activity of drug metabolizing enzymes is presumed to be mainly responsible for the increased drug clearance observed in epileptic subjects.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7117357     DOI: 10.1007/bf00542550

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  22 in total

1.  Liver blood flow and blood volume following chronic phenobarbitone administration.

Authors:  E E Ohnhaus; J T Locher
Journal:  Eur J Pharmacol       Date:  1975-04       Impact factor: 4.432

2.  The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function.

Authors:  J CAESAR; S SHALDON; L CHIANDUSSI; L GUEVARA; S SHERLOCK
Journal:  Clin Sci       Date:  1961-08       Impact factor: 6.124

3.  The behavior of intravenously injected particulate material; its rate of disappearance from the blood stream as a measure of liver blood flow.

Authors:  E L DOBSON; H B JONES
Journal:  Acta Med Scand Suppl       Date:  1952

4.  Influence of phenobarbital on factors responsible for hepatic clearance of indocyanine green in the rat: relative contributions of induction and altered liver blood flow.

Authors:  D G McDevitt; A S Nies; G R Wilkinson
Journal:  Biochem Pharmacol       Date:  1977-07-01       Impact factor: 5.858

5.  Induction of liver growth by xenobiotic compounds and other stimuli.

Authors:  R Schulte-Hermann
Journal:  CRC Crit Rev Toxicol       Date:  1974-09

6.  The stimulant effect of drugs on indocyanine green clearance by the liver.

Authors:  V Melikian; J D Eddy; A Paton
Journal:  Gut       Date:  1972-10       Impact factor: 23.059

7.  Changes in liver blood flow during enzyme induction.

Authors:  E E Ohnhaus; S S Thorgeirsson; D S Davies; A Breckenridge
Journal:  Biochem Pharmacol       Date:  1971-10       Impact factor: 5.858

8.  Comparison of three methods of measuring liver blood flow.

Authors:  H Pirttiaho; U Pitkänen; M Rajasalmi; A Ahonen
Journal:  Acta Radiol Diagn (Stockh)       Date:  1980

9.  The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man.

Authors:  C J Roberts; L Jackson; M Halliwell; R A Branch
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

10.  Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow.

Authors:  R A Branch; D G Shand; G R Wilkinson; A S Nies
Journal:  J Clin Invest       Date:  1974-04       Impact factor: 14.808

View more
  15 in total

Review 1.  Antiepileptic-induced resistance to neuromuscular blockers: mechanisms and clinical significance.

Authors:  Sulpicio G Soriano; J A Jeevendra Martyn
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

2.  The influence of long-term anticonvulsant therapy with diphenylhydantoin and carbamazepine on serum gamma-glutamyltransferase, aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase.

Authors:  H G Aldenhövel
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1988

Review 3.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 4.  Human relevance of rodent liver tumour formation by constitutive androstane receptor (CAR) activators.

Authors:  Brian G Lake
Journal:  Toxicol Res (Camb)       Date:  2018-03-12       Impact factor: 3.524

5.  Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man.

Authors:  H H Kupferschmidt; K E Fattinger; H R Ha; F Follath; S Krähenbühl
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

6.  Interaction between cyclosporin A and phenobarbitone.

Authors:  H Carstensen; N Jacobsen; H Dieperink
Journal:  Br J Clin Pharmacol       Date:  1986-05       Impact factor: 4.335

7.  Identification of an inducible form of cytochrome P-450 in human liver.

Authors:  P B Watkins; S A Wrighton; P Maurel; E G Schuetz; G Mendez-Picon; G A Parker; P S Guzelian
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

8.  A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients.

Authors:  E Perucca; A Hedges; K A Makki; M Ruprah; J F Wilson; A Richens
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

9.  The effect of liver microsomal enzyme inducing and inhibiting drugs on insulin mediated glucose metabolism in man.

Authors:  J T Lahtela; B Gachalyi; S Eksymä; A Hämäläinen; E A Sotaniemi
Journal:  Br J Clin Pharmacol       Date:  1986-01       Impact factor: 4.335

10.  Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients.

Authors:  A Tartara; C A Galimberti; R Manni; L Parietti; C Zucca; H Baasch; L Caresia; W Mück; N Barzaghi; G Gatti
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.